These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 22946949)

  • 21. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials.
    Tsong Y; Wang W
    J Biopharm Stat; 2012 Sep; 22(5):875-8. PubMed ID: 22946936
    [No Abstract]   [Full Text] [Related]  

  • 24. Sample size allocation in multiregional equivalence studies.
    Liao JJZ; Yu Z; Li Y
    Pharm Stat; 2018 Sep; 17(5):570-577. PubMed ID: 29911346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.
    Sugimoto T; Sozu T; Hamasaki T
    Pharm Stat; 2012; 11(2):118-28. PubMed ID: 22415870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size allocation to regions in a multiregional trial.
    Uesaka H
    J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the impact of endpoint shopping on power in confirmatory clinical trials.
    Wiens BL
    J Biopharm Stat; 2003 May; 13(2):229-40. PubMed ID: 12729391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Method of balanced adjustment in testing co-primary endpoints.
    Kordzakhia G; Siddiqui O; Huque MF
    Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size determination in clinical trials with multiple co-primary binary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    Stat Med; 2010 Sep; 29(21):2169-79. PubMed ID: 20687162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing consistency across all regions in a multi-regional clinical trial.
    Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF
    Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type I error and power in noninferiority/equivalence trials with correlated multiple endpoints: an example from vaccine development trials.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2004 Nov; 14(4):893-907. PubMed ID: 15587971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.